Itse pohtinut sitä että mikä mahtaa olla isojen lääkeyhtiöiden mielenkiinto tehdä rokote, joka antaa vastustuskyvyn koronalle pitkäksi aikaa? Pelkään että sitä ei ole, koska ei kannata taloudellisesti vaan mielummin myydään rokotetta 4-6kk välein. Ja toiseksi näyttää siltä ettei tuolla mRNA-rokoitteella edes voi tehdä pitkäaikaista vastustuskykyä (mistään en mitään tiedä kunhan katselen taulukoita)..
Suomessa on kaks rokotetta kehitteillä. Toinen oli vaatimattomasti tavotteena ''maailman paras''. Mihin itseasiassa aidosti uskon.
Toinen on kalle sakselan nenäsumute. Sai tänä vuonna muistaakseni 9miljoonan rahotuksen.
Rupesin tutkimaan ihan piruuttani rokotuksia. Mielenkiintosta infoa(minusta ainakin):
The California-based company
Arcturus Therapeutics and
Duke-NUS Medical School in Singapore have developed an mRNA vaccine called ARCT-021.
Tämä on yhdistetyssä phase2/3:ssa.
The South Korean company
Genexine started testing the safety of a DNA-based vaccine in June 2020.
Phase 2/3
Pennsylvania-based company
Inovio developed DNA-based vaccines that are delivered into the skin with electric pulses from a hand-held device. (
)
Phase2:ssa.
Canada’s
Providence Therapeutics specializes in messenger RNA vaccines to treat cancer. In response to the pandemic, they developed an mRNA vaccine against the coronavirus. They launched a
Phase 1 study of an RNA vaccine in late January 2021, and in May
announced that the vaccine appeared safe and produced promising levels of antibodies. In August, Providence Therapeutics launched a
Phase 2 trial.
Zydus Cadila began
testing a DNA-based vaccine delivered by a skin patch. After getting
promising results in their Phase 1 trial, they launched a
Phase 2 trial on ZyCoV-D on Aug. 6. On Jan. 3, 2021 the Indian government gave Zydus Cadila
permission to advance to a
Phase 3 trial with 30,000 volunteers.
Intiassa vissiin jo käytössä.
Covaxin, produced by Bharat Biotech, was the first vaccine for Covid-19 developed in India to gain emergency use authorization. India approved it in April 2021, and the World Health Organization gave it emergency use listing on Nov. 3.
Intiassa käytössä kanssa.
edit. japanilainen
Shionogi, a Japanese pharmaceutical giant,
launched a Phase 1/2 trial of a coronavirus vaccine on Dec. 16. The company developed it in collaboration with the National Institute of Infectious Diseases and Kyushu University. The vaccine is based on a coronavirus protein which is produced in insect cells by genetically altered viruses. But according to a
March report from The Japan Times, Shionogi has faced difficulties with recruiting enough participants for its trials, and it is unlikely that the vaccine will be ready by the end of 2021. In a
slide deck from its Aug. 2 conference call with investors, Shionogi said that it is using a new adjuvant with its vaccine after receiving disappointing preliminary results from the original trial. A new Phase 1/2 trial began in July 2021, they said. On Oct. 21, the company
announced that it had moved to a Phase 2/3 trial.
SItten tää gsk joka oli suomen valtion ykkös hanke, mut se viivästy.
Last spring, researchers at the
University of Washington developed a nanoparticle studded with pieces of the coronavirus spike protein.
Experiments on mice showed a strong immune response. The South Korean vaccine company
SK Bioscience licensed the vaccine, called
GBP510. After
partnering with GSK, they launched a
Phase 1/2 trial of the vaccine in February 2021. Genetic Engineering and Biotechnology News
reported that people who received the vaccines made five to eight times more antibodies than people who recovered from Covid-19. SK Bioscience has received
$210.1 million from the Coalition for Epidemic Preparedness Innovations for the development of GBP510. In August, the
company launched
a Phase 3 trial,
comparing GBP510 to AstraZeneca’s Vaxzevria vaccine. SK Bioscience expects results in the first half of 2022.
Mä ihan aidosti uskon, et ens vuoden aikana, korona hyvin hyppysissä. Monta rokotetta tulossa. On phase 2 ja 3ssa jo. EIkä kaikki ole mrna.
edit 2. eli gsklla on kaks eri hanketta. tää on vissiin se mitä tarkotin: gsk sanofi
In early 2020,
Sanofi developed a Covid-19 vaccine based on viral proteins they produced with engineered viruses that grow inside insect cells.
GSK supplemented these proteins with adjuvants that stimulate the immune system. The vaccine, called Vidprevtyn, is based on the same design Sanofi used to create
Flublok, an approved vaccine for influenza. The companies
launched a Phase 1/2 clinical trial in September 2020.
Vidprevtyn was widely expected to play a major role in tackling the pandemic. In the United States, Operation Warp Speed selected it as one of six vaccines to secure in large quantities, reaching a
$2.1 billion agreement for 100 million doses. On Sept. 18 Sanofi closed another deal
with the European Union for 300 million doses for an unspecified amount, and later reached
an agreement with Canada for up to 72 million doses. In addition, Sanofi agreed to provide
200 million doses to COVAX, an international collaboration to deliver the vaccine equitably across the world. The company expected to move to a Phase 3 trial in December and potentially seek emergency use authorization for Vidprevtyn in the United States by spring 2021. Sanofi announced plans to make up to one billion doses in 2021.
But on Dec. 11, 2020, Sanofi and GSK
announced that Vidprevtyn was proving disappointing. While it provided promising levels of antibodies in people under 50, older people did not respond as strongly as they had hoped. The company halted the trial. In January Sanofi
decided to help Pfizer and BioNTech make 100 million doses of their vaccine, and they reached
a similar agreement with Johnson & Johnson in February.
Muillekin työkavereille sanottu samaa kun ovat sairaana olleet ettei tarvi käydä testissä.
